< Voltar à página inicial

PP-UNP-BRA-4499

Referências
Solomon B, Bauer TM, Sai-Hong Ignatius Ou, Liu G, Hayashi H, Bearz A, et al. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study. 2022 May 23;40(31):3593–602.
 Solomon B, Bauer TM, De Marinis F, Felip E, Goto Y, Liu G, et al. LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study. Annals of Oncology. 2020 Sep;31:S1180–1.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England journal of medicine [Internet]. 2013 [cited 2019 Mar 4];368(25):2385–94. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23724913
Hida, Toyoaki, et al. “Alectinib versus Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer (J-ALEX): An Open-Label, Randomised Phase 3 Trial.” The Lancet, vol. 390, no. 10089, 1 July 2017, pp. 29–39, www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30565-2/fulltext, https://doi.org/10.1016/S0140-6736(17)30565-2. Accessed 14 Jan. 2023.
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-lorlatinib-metastatic-alk-positive-nsclc
Lorbrena® | Pfizer Brasil [Internet]. www.pfizer.com.br. [cited 2023 Oct 5]. Available from: https://www.pfizer.com.br/bulas/lorbrena
https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/novos-medicamentos-e-indicacoes/lorbrena-r-lorlatinibe
Preeshagul, Isabel R, et al. “EP12.02-11 Sequencing Patterns and Treatment Effectiveness in ALK-Positive ANSCLC Following First-Line Alectinib or Brigatinib.” Journal of Thoracic Oncology, vol. 18, no. 11, 1 Nov. 2023, pp. S678–S679, https://doi.org/10.1016/j.jtho.2023.09.1304. Accessed 22 Jan. 2024.
Le, Hien, et al. “EP12.02-02 Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ MNSCLC Receiving ALK TKIs.” Journal of Thoracic Oncology, vol. 18, no. 11, 1 Nov. 2023, pp. S674–S674, https://doi.org/10.1016/j.jtho.2023.09.1295. Accessed 22 Jan. 2024.